SCHEMBL3486841

SCHEMBL3486841

C[C@H](N)C(=O)OC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.58
PKM P14618 1/20 0.58
PTGS1 P23219 1/20 0.58
XIAP P98170 1/20 0.58
SLC7A5 Q01650 1/20 0.58
SLC15A1 P46059 2/20 0.50
SLC6A2 P23975 2/20 0.48
TAAR1 Q96RJ0 2/20 0.48
MAOA P21397 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
CYP2A6 P11509 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
ANPEP P15144 2/20 0.48
RNPEP Q9H4A4 2/20 0.48
DNPEP Q9ULA0 2/20 0.48
LTA4H P09960 2/20 0.47
CTRB1 P17538 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8835936 0.91 SLC7A5 (0.68) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL288607 0.91 SLC7A5 (0.68) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL28820471 0.91 SLC7A5 (0.68) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL29160724 0.90 SLC7A5 (0.66) ALPIPKMPTGS1XIAPSLC7A5
Tyrosine SCHEMBL2284684 0.89 SLC7A5 (0.63) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL27978089 0.89 ALPI (0.56) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL1679191 0.87 ALPI (0.54) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL27978358 0.87 ALPI (0.54) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL27978312 0.87 ALPI (0.54) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL208390 0.87 ANPEP (0.57) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115896059-A Cyclodextrin glycosyltransferase mutant for preparing rebaudioside RM, coding gene and application thereof 三元生物工程研究(天津)有限公司 2023-04-04 CN claimed
CN-107667293-A Diagnostic tool for Ah Hereby sea Mo's disease 法奈科斯公司 2018-02-06 CN claimed
US-20100041612-A1 Fragments of the Glucagon-Like Peptide-1 and Uses Thereof NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. 2010-02-18 US claimed
US-20090105134-A1 C-Terminally Pegylated Growth Hormones NOVO NORDISK A/S (DK) 2009-04-23 US claimed
WO-2007030706-A1 FRAGMENTS OF THE GLUCAGON-LIKE PEPTIDE-I AND USES THEREOF NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) 2007-03-15 WO claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
CN-117551032-A Drug conjugates comprising quinoline derivatives 国家科学研究中心 2024-02-13 CN disclosed
CN-112955434-B Drug conjugates comprising quinoline derivatives 国家科学研究中心 2023-12-08 CN disclosed
WO-2023224577-A1 INHALATION COMPOSITIONS COMPRISING MICRONIZED HUMAN INSULIN Arven Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) 2023-11-23 WO disclosed
CN-112094856-B Transaminase mutant and application thereof in sitagliptin synthesis 国药集团威奇达药业有限公司 2023-06-27 CN disclosed
CN-116162562-A Lactobacillus delbrueckii subspecies and culture method and application thereof 深圳市盐田区人民医院 2023-05-26 CN disclosed
CN-114164134-B Bifidobacterium longum subspecies longum with functions of preventing and relieving colitis symptoms and application thereof 东北农业大学 2023-03-03 CN disclosed
CN-114667298-A SIGLEC-9ECD fusion molecules and methods of use thereof 艾利妥 2022-06-24 CN disclosed
EP-1465908-A4 COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES BRISTOL MYERS SQUIBB CO (US) 2005-11-30 EP disclosed
EP-1572991-A2 COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES Bristol-Myers Squibb Company (US) 2005-09-14 EP disclosed
EP-1465908-A2 COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES Bristol-Myers Squibb Company (US) 2004-10-13 EP disclosed
WO-2004078978-A1 COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-16 WO disclosed
WO-2004061116-A2 COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-07-22 WO disclosed
WO-2003057830-A2 COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-17 WO disclosed
WO-1993005011-A1 NOVEL IMMUNOSUPPRESSANTS SANDOZ LTD. (CH) 1993-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105134-A1 C-Terminally Pegylated Growth Hormones GHRHR, GHITM, HDGF ALPI 2242/4885PKM 4447/4885PTGS1 3835/4885
US-20100041612-A1 Fragments of the Glucagon-Like Peptide-1 and Uses Thereof GLP1R, IAPP, GIPR ALPI 1589/4885PKM 3342/4885PTGS1 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.